STOCK TITAN
  1. Home
  2. Sec-filings
  3. ANIP
  4. [Form 4] ANI PHARMACEUTICALS INC Insider Trading Activity

ANI Pharmaceuticals (ANIP) counsel Meredith Cook sells 500 shares under 10b5-1 plan

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

ANI Pharmaceuticals Inc. insider Meredith Cook, Senior Vice President, General Counsel and Secretary, reported a sale of 500 shares of common stock on August 13, 2026 at $75.48 per share. After this transaction, Cook directly holds 74,424 shares of ANI Pharmaceuticals common stock. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on September 15, 2025.

Positive

  • None.

Negative

  • None.
Insider Cook Meredith
Role SR. VP, GENERAL COUNSEL & SEC.
Sold 500 shs ($38K)
Type Security Shares Price Value
Sale Common Stock F1 500 $75.48 $38K
Holdings After Transaction: Common Stock — 74,424 shares (Direct)
Footnotes (1)
  1. F1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.
Shares sold 500 shares Common Stock sale on August 13, 2026
Sale price per share $75.48 per share Price for the 500-share sale of Common Stock
Shares owned after transaction 74,424 shares Directly owned Common Stock following the August 13, 2026 sale
Rule 10b5-1 plan adoption date September 15, 2025 Date the trading plan governing this sale was adopted
Rule 10b5-1 trading plan regulatory
"The sale was effected pursuant to a Rule 10b5-1 trading plan adopted"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Form 4 regulatory
"The sale reported in this Form 4 was effected pursuant to a Rule"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
non-derivative financial
"The transaction is classified as a sale of non-derivative common stock"

FAQ

What insider transaction did ANI Pharmaceuticals (ANIP) report for Meredith Cook?
ANI Pharmaceuticals reported that Meredith Cook sold 500 shares of common stock at $75.48 per share on August 13, 2026. The transaction is classified as a sale of non-derivative common stock.

How many ANI Pharmaceuticals (ANIP) shares does Meredith Cook hold after the sale?
After the reported transaction, Meredith Cook directly holds 74,424 shares of ANI Pharmaceuticals common stock. This figure reflects her position immediately following the August 13, 2026 sale of 500 shares.

Was the ANI Pharmaceuticals (ANIP) insider sale under a Rule 10b5-1 plan?
Yes. The filing states the sale was effected pursuant to a Rule 10b5-1 trading plan adopted by Meredith Cook on September 15, 2025. Such plans prearrange trades according to specified parameters.

What role does Meredith Cook hold at ANI Pharmaceuticals (ANIP)?
Meredith Cook serves as Senior Vice President, General Counsel and Secretary at ANI Pharmaceuticals. The reported Form 4 transaction reflects trading activity by an executive officer of the company.

What type of security did Meredith Cook trade in ANI Pharmaceuticals (ANIP)?
The transaction involved Common Stock of ANI Pharmaceuticals. It was reported as a non-derivative transaction, meaning it related to actual shares rather than options or other derivative securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cook Meredith
(Last)(First)(Middle)
C/O ANI PHARMACEUTICALS, INC.
104 CARNEGIE CENTER, SUITE 300
(Street)
PRINCETON NEW JERSEY 08540
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
SR. VP, GENERAL COUNSEL & SEC.
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/13/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/13/2026S(1)500D$75.4874,424D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.
Remarks:
/s/ Meredith W. Cook08/13/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR